OCUL
NasdaqOcular Therapeutix, Inc.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$43.5M
2021
$51.5M
2022
$58.4M
2023
$63.7M
2024
$52.0M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$52.0M
Net Income$-265.9M
Gross Profit—
Oper Income$-270.0M
EPS (dil)$-1.42
Rev/sh$0.24
FCF/sh$-0.99
Book/sh$2.99
Gross M—
Oper M-519.8%
Profit M-511.9%
FCF M-417.5%
ROE-40.6%
ROA-32.9%
ROIC—
R&D/Rev379.4%
Rev Y/Y-18.5%
Rev 3Y CAGR0.3%
EPS Y/Y-16.4%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+18.3%
Current Ratio15.39
Quick Ratio15.32
Debt/Eq0.03
Int Coverage-22.8×
Net Debt$720.7M cash
Total Debt$18.0M
Cash & Eq$738.7M
Total Assets$808.1M
Oper CF$-204.9M
Capex$12.0M
Free CF$-216.9M
Buybacks—
Equity$654.3M
Liabilities$153.7M
Shs Outstand0.22B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-78.0M | $-78.7M | $-82.4M | $-171.8M | $-270.0M |
| Net Income | $-6.6M | $-71.0M | $-80.7M | $-193.5M | $-265.9M |
| Diluted EPS | $-0.98 | $-0.97 | $-1.02 | $-1.22 | $-1.42 |
| Operating Cash Flow | $-65.5M | $-59.6M | $-70.2M | $-134.7M | $-204.9M |
| Free Cash Flow | $-66.7M | $-63.3M | $-76.3M | $-136.0M | $-216.9M |
COMMUNITY · $OCUL0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.